Traders should monitor the April 16 KOL webinar for additional clinical insights and potential commentary on commercial rollout. The significant reduction in grafting time and high satisfaction may drive increased adoption, especially if supported by full dataset in 2026.
Price Chart
Executive Summary
AVITA Medical announced positive interim results from its Cohealyx-I study, showing a statistically significant reduction in time to skin grafting (mean 13.6 days vs. 33.2 days benchmark), with high investigator satisfaction. The data supports potential broader clinical adoption of Cohealyx, a collagen-based dermal matrix, ahead of a KOL webinar on April 16.
Key Facts
- Interim results from 40 patients in the Cohealyx-I study show mean time to grafting reduced to 13.6 days vs. 33.2 days in the benchmark (p<0.001), a ~20-day improvement.
- Median time to grafting was 11 days, with 25% grafted within 7 days and 72% within 14 days.
- Investigators reported 90% satisfaction at time of grafting, including first-time users.
- Data will be presented at a KOL webinar on April 16, 2026, during the American Burn Association Annual Meeting.
- Cohealyx is a collagen-based dermal matrix designed to optimize wound bed preparation for autografting.
Financial Impact
Potential for increased market penetration and revenue growth from Cohealyx, though no financial figures were disclosed.
Risk Factors
- Results are interim and based on only 40 patients; final outcomes may differ.
- Cohealyx is still in post-market evaluation; regulatory or reimbursement hurdles could limit adoption.
- Company operates on OTC with low market cap ($151M), increasing volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273241 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | Press Release | $15.29 | awaiting T+60 | — | $15.51 (+1.44%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.49 | awaiting T+60 | — | $15.51 (+34.99%) |
Aug 9, 2026 11w ago | Press Release | $7.60 | awaiting T+60 | — | $15.51 (+104.08%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.97 $11.20 | ▼ −182.12% | ▼ −177.72% | $15.51 (−290.68%) |
May 17, 2026 23w ago | Press Release | $4.19 | awaiting T+60 | — | $15.51 (+270.17%) |
Apr 30, 2026 25w ago | Press Release | $4.32 $4.75 | ▲ +9.95% | ▲ +6.85% | $15.51 (+259.03%) |
Apr 23, 2026 26w ago | Press Release | $4.46 $5.09 | ▲ +14.13% | ▲ +9.05% | $15.51 (+247.76%) |
Apr 14, 2026 27w ago | Press Release | $5.60 $4.41 | ▼ −21.25% | ▼ −29.77% | $15.51 (+176.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers